NO20015021D0 - Fremgangsmåte til å nedregulere IL-5 aktivitet - Google Patents

Fremgangsmåte til å nedregulere IL-5 aktivitet

Info

Publication number
NO20015021D0
NO20015021D0 NO20015021A NO20015021A NO20015021D0 NO 20015021 D0 NO20015021 D0 NO 20015021D0 NO 20015021 A NO20015021 A NO 20015021A NO 20015021 A NO20015021 A NO 20015021A NO 20015021 D0 NO20015021 D0 NO 20015021D0
Authority
NO
Norway
Prior art keywords
regulating
activity
Prior art date
Application number
NO20015021A
Other languages
English (en)
Other versions
NO20015021L (no
Inventor
Steen Klysner
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of NO20015021D0 publication Critical patent/NO20015021D0/no
Publication of NO20015021L publication Critical patent/NO20015021L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20015021A 1999-04-23 2001-10-15 Fremgangsmåte til å nedregulere IL-5 aktivitet NO20015021L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900552 1999-04-23
US13281199P 1999-05-06 1999-05-06
PCT/DK2000/000205 WO2000065058A1 (en) 1999-04-23 2000-04-19 Method for down-regulating il5 activity

Publications (2)

Publication Number Publication Date
NO20015021D0 true NO20015021D0 (no) 2001-10-15
NO20015021L NO20015021L (no) 2001-12-21

Family

ID=26064209

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015021A NO20015021L (no) 1999-04-23 2001-10-15 Fremgangsmåte til å nedregulere IL-5 aktivitet

Country Status (19)

Country Link
US (2) US7285273B1 (no)
EP (1) EP1173573A1 (no)
JP (1) JP2002543098A (no)
KR (1) KR20020084841A (no)
CN (1) CN1355846A (no)
AU (1) AU777952B2 (no)
CA (1) CA2370391A1 (no)
CZ (1) CZ20013709A3 (no)
EA (1) EA200101125A1 (no)
EE (1) EE200100552A (no)
HR (1) HRP20010824A2 (no)
HU (1) HUP0200958A3 (no)
IL (1) IL145786A0 (no)
MX (1) MXPA01010625A (no)
NO (1) NO20015021L (no)
PL (1) PL351986A1 (no)
SK (1) SK14832001A3 (no)
TR (1) TR200103046T2 (no)
WO (1) WO2000065058A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
CN1321695C (zh) * 2001-11-07 2007-06-20 赛托斯生物技术公司 用于治疗变应性嗜酸细胞性疾病的展示il－5、il－3或嗜酸细胞活化趋化因子的抗原阵列
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
KR20050044857A (ko) * 2001-11-16 2005-05-13 파멕사 에이/에스 무차별 ｔ 세포 에피토프 삽입물을 갖는 멀티머 단백질의면역원성 모방체
WO2004019974A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
EP1534323A2 (en) * 2002-08-30 2005-06-01 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
MXPA05010222A (es) * 2003-03-24 2006-05-22 Mercia Pharma Llc Metodos y composiciones para tratar y prevenir condiciones inflamatorias.
CN103091499B (zh) * 2013-01-23 2015-07-08 三峡大学 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用
CA2900824A1 (en) * 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
WO2014164640A1 (en) * 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
CN113307869B (zh) * 2020-10-30 2023-01-06 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
AU4377793A (en) 1992-05-20 1993-12-13 Johns Hopkins University, The Alternative receptor therapy
US5616488A (en) 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
ATE415173T1 (de) 1993-09-14 2008-12-15 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
CN1146772A (zh) * 1994-03-28 1997-04-02 美国联合生物医学公司 用于治疗过敏反应的合成肽免疫原
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
ATE196297T1 (de) * 1994-05-18 2000-09-15 Synthetic Peptides Inc Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
WO1997000321A1 (en) * 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
CA2751712C (en) * 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
EP1005374B1 (en) 1997-01-22 2007-04-18 Zycos Inc. Microparticles for delivery of nucleic acid
WO1998047923A1 (en) 1997-04-18 1998-10-29 Tanox Biosystems, Inc. Il-5r antagonists for treatment of inflammation, asthma and other allergic diseases
EE200100203A (et) * 1998-10-05 2002-10-15 M & E Biotech A/S Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon

Also Published As

Publication number Publication date
IL145786A0 (en) 2002-07-25
WO2000065058A1 (en) 2000-11-02
HUP0200958A2 (en) 2002-06-29
EE200100552A (et) 2002-12-16
TR200103046T2 (tr) 2002-06-21
EA200101125A1 (ru) 2002-04-25
US6746669B1 (en) 2004-06-08
SK14832001A3 (sk) 2003-02-04
HRP20010824A2 (en) 2002-12-31
CA2370391A1 (en) 2000-11-02
AU4100800A (en) 2000-11-10
HUP0200958A3 (en) 2004-11-29
US7285273B1 (en) 2007-10-23
CN1355846A (zh) 2002-06-26
EP1173573A1 (en) 2002-01-23
NO20015021L (no) 2001-12-21
MXPA01010625A (es) 2003-09-04
JP2002543098A (ja) 2002-12-17
CZ20013709A3 (cs) 2002-11-13
PL351986A1 (en) 2003-07-14
AU777952B2 (en) 2004-11-04
KR20020084841A (ko) 2002-11-11

Similar Documents

Publication Publication Date Title
NO20015021D0 (no) Fremgangsmåte til å nedregulere IL-5 aktivitet
NO20016252L (no) Fremgangsmåte for nedregulering av GDF-8 aktivitet
NO20004550D0 (no) Enzyminhibitorer
DE60024731D1 (de) Ritzgerät
DE60012447D1 (de) Datendekompression
NO331109B1 (no) Fremgangsmate for a utvide et rorformet element i en bronn
ID27346A (id) Peralatan pengenal suara
DE60044218D1 (de) em
DE60024754D1 (de) Aufzeichnungsgerät
DE60010553D1 (de) Interferenzunterdrückungsverfahren
DE60032034D1 (de) Aufzeichnungsgerät
DE69916133D1 (de) Elektro-neuro-adaptiver stimulator
ITMI991895A0 (it) Depigmentanti cutanei
DE60037785D1 (de) Wellenformentzerrer
DE60030196D1 (de) Aufzeichnungsgerät
DE50007090D1 (de) Autothermer reformierungsreaktor
DE60037210D1 (de) Datenumwandlungs- und Kommunikationsverfahren
DE29907598U1 (de) Erdungskontakt
NO992816D0 (no) Ikke-numerisk klokke
FI19992370A (fi) Menetelmä kaupankäynnin varmistamiseksi
NO20022047L (no) Avstandselement
NO20006198L (no) Fremgangsmåter for å inhibere TEF-3-aktivitet
UA34042A (uk) Спосіб моделювання гідроуретеронефрозу
NO992291D0 (no) Datamus
DK1043026T3 (da) Melanombehandling

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application